BAB VI PEMBAHASAN
VII.2 Saran
1. Perlu dilakukan penelitian terhadap ekspresi p53 mutan pada galur sel karsinoma kolon yang lain atau penelitian secara invivo dengan konsentrasi pada LC50dan atau di bawahnya.
2. Perlu dilakukan penelitian dalam bidang biologi molekuler lebih lanjut mengenai pengaruh ekstrak bawang dayak terhadap pertumbuhan sel karsinoma kolon HT29, khususnya terhadap produk downstream dari protein p53 seperti p21, puma ,noxa, bax dan lain – lain..
3. Perlu dilakukan penelitian lain mengenai genomik p53 dengan aras DNA/mRNA
DAFTAR PUTAKA
1. Kelompok Kerja Adenokarsinoma Kolorektal,. 2006., Panduan Pengelolaan
Adenokarsinoma Kolorektal,. pp. 1-56.
2. Tjarta, A,. 2001. Neoplasia : In Patologi Umum,. Sagung Seto,. Jakarta,. pp. 198 -199
3.
Ashariati, A,. 2004., Adjuvant Chemotherapy of Colorectal Cancer,. In: Recent Advancesand Challenges In General Surgeons in Indonesia,. Surabaya,.
4. Helena, R, C,. Kirby, I, B,. 1997,. Tumors of the Colon, In: Maingot’s Abdominal
Operations,. Volume II, Tenth edition , Appleton & Lange, USA, pp.1281-1301
5. Tannock, I.E. Hil, R.P. 1998, . The Basic Science of Oncology, 3rd Edition, Mc Graw
Hill, Singapore.
6. Alfred, M, C,. Bruce,D, M,. 1997., Cancer of The Colon,. In : Cancer, Principles &
Practice of Oncology., 5
thEd,. Editors : Devita. V, T., Lippincott-Raben., USA.,
pp. 1144- 1185
7. Kodner, I,J,. Robert, D, F,. 1999.. Colon, Rectum, and Anus., In : Principles of
Surgery,. 7
thEd., Vol. 2., Editors : Seymour I. Schwartz., McGraw-Hill Health
Professions Division., NBew York., USA., pp. 1265 – 1380.
8. Allen, J,I,. 1995,. Molecular Biology of Colorectal Cancer : a Clinician’s View,.
Perspect Colon Rectal Surgery., 8: 181 m- 202.
9. Carolyn, C,. Compton,. 2005., The Staging of Colorectal Cancer: 2004 and Beyond,.
Ca Cancer Journal for Clinicians,., Vol. 54. No. 6. pp. 295 – 308.
10. Soetamto, W, P,. 2004., Pembedahan Karsinoma Kolon dan Rektum,. In : Recent
Advance and Challenges in General Surgeon in Indonesia,. pp. 12-19.
11. Sjamsuhidayat, R,. Wim, D, J,. 1997., Buku Ajar Ilmu Bedah,. EGC,. Jakarta,. pp.
876-99
12. Janne, P, A,. 2000., Chemoprevention of colorectal cancer,. The New England
Journal of Medicine. Vol. 342. no. 26: pp. 1960 – 1966.
13. Murti, B., 1996,, Penerapan Metode Statistik Nonparametrik untuk Ilmu-ilmu
Kesehatan, Gramedia Pustaka Utama, Jakarta, hal:37
14. Sudigdo, S,A,. Ismael, S,. 2002., Dasar-dasar Metodologi Penelitian Klinis., ed.
2.,Sagung Seto., Jakarta,
15. Budiani, D,R,. Retnaningsih, D,. et al ,. 2005.. Expression of LMP1 in Javanese
Colon Carcinoma Patient’s with Duke’s classification System : indicated The
Association of Epstein-Barr Virus infection In colon malignancies., Department
of Patology anatomy, school of medicine, Sebelas Maret University, Surakarta,.
16. Arief T.Q.M., 2004, Pengantar Metodologi Penelitian untuk Ilmu Kesehatan,
Cetakan Kedua, Penerbit CSGF, Klaten
17. Compton C.C., 2005, The Staging of Colorectal Cancer : 2004 and Beyond, Ca
Cancer Journal for Clinicians, Vol. 54. No. 6, pp. 295 – 308
18. Katzung B.G., 2001, Basic & Clinical Pharmacology, 8
thEd, Mc Graw-Hill
Companies, Philadelphia
19. Pusztai L., et al., 1996, Cell Proliferation in Cancer ; Regulatory Mechanisms of
Neoplastic Cell growth, Oxford University Press, New York
20. Shengli C., 2001, Cell Cycle and Tumor Suppressor Genes, Charles Cai Tech, edit
Tom Beron, pp. 1 – 36
21. Sigma A, 2007, HT29 Cell Line Human Colon Adenocarcinoma,
http://sigmaaldrich.com
22. Teich N.M., 1997, Oncogenes and Cancer, In : Cellular and Molecular Biology of
Cancer 3
rdEd, Editors : Franks L.M., Teich N.M., Oxford University Press, New
York, pp. 169 – 201
23. Tim Skripsi FK UNS., 2007, Buku Panduan Skripsi, Fakultas kedokteran Universitas
Sebelas Maret, Surakarta
24. Wolf J.C, Ginn P.E, HomerB, Fox L.E, Kurzman I.D., 1997 Immunohistochemical
Deecion of p53 Tumor Suppressor Gene Protein in Canine Epithelial Colorectal
Tumors.Vet Pathol;34:394-404
25. leonart ME, Vidal F,Gallardo D, Fuertez MD, Rojo F, Cuatrecasas M et all , 2006,
New p53 Related Genes in Human Tunord:Significant down reguatin in Colon and
Lung Carcinoma .Onkology reports;16:603-608
26. Petak I, Tilman DM, Hougthon JA. 2000, P53 Dependence of Fas Induction and
Acute Apoptosis in Response to 5-Fluorouracil-Leucovrin in Human Colon
Carcinoma Cell Lines. Clinical Cancer Research;6:4432-4441
27. Yang B, Stambrook P.J, Markowitz S.D, 1996. Wild Type p53 Demonstrates
Functional Dominance in a Human Colon Carcinoma Cell Line in which it induces
Reversible Growth Arrest. Clnical Cancer Research;2:1639-1647
28. Deiry W.S.Colon Cancer,Adenocarcinoma.http://www.emedicine.com diakses pada
tanggal 23/9/2007
29. Shalkow J. Colorectal Tumor. http://www.emedicine.com diakses pada tanggal
23/9/2007
30. Cirinaone E. Rectal Cancer. http://www.emedicine.com diakses pada tanggal
23/9/2007
31. Hassan I.Colon,Adenocarcinoma. http://www.emedicine.com diakses pada tanggal
23/9/2007
32. Tullo A, D’erchia A.M, Honda K, Mitry R.R, Kelly M.D, Hbib N.A,
1999.Characterization of p53 mutations in colorectal liver metastases and
correlation with clinical parameters.Clinical Cancer Research;5:3523-3528
33. Slatery M.L, Curtin K, Edwards S, Schaffer D, Anderson K, Samowitz W., 2002
Diet,activity and lifestyle associations with p53 mutations in colon tumor.Cancer
Epydemiology,Biomarker&Prevention .;11:541-548
34. Chen F, Chang D, Goh M, Klibanov S, Ljungman M. 2000. Role of p53 in Cell Cycle
Regulation and Apoptosis following Exposure to Proteasome Inhibitor.;11:239-246
35. Tjarta A, 1973, Neoplasma in PATOLOGI. Bagian Patologi Anatomik Fakultas
Kedokteran Universitas Indonesia,pp:77-82
36. Pusztai, L,. et al., 1996., Cell Proliferation in Cancer ; Regulatory Mechanisms of
Neoplastic Cell growth., Oxford University Press.,
37. Anonim,2002.The Central Role of p53 Cell-Cycle Arrest, DNA Repair and Apoptosis
Following UV Irradiation.http://www.expertreviews.org/
38. Basu A.,Haldar S.,1998. The Relationship between Bcl2,Bax and p53:Qonsequences
for cell cycle progression and cell death.Molecular Human
Reproduction;4:1099-1109.
39. Mohanna M.A.,Khodairy F.M.,Krezolek Z.,Bertilsson P.,Houssein K.A.,Aboussekhra
A,2001.p53 is dispensable for UV-induced cell cycle arrest at late G1 in mammalian
cells. Carcinogenesis;22:573-578.
40. Rotter V, 2002.Expression of the wild type p53 tumor supressor gene in normal cells
and its deregulation in cancer cells. Departement of Molecular Cell Biology
:p:176-177.
41. Offer H.,Zurer I.,Bontalvi G.,Reha’k M.,Falcovitz A.,Milyavsky M.,et all,2001. P53
modulates base excission repair activity in a cell cycle-spesific Manner after
Genotoxic Stress. Cancer Research;61:88-96.
42. Sato T.,Koseki T.,Yamato K.,Saiki K.,Konishi K.,Yoshikawa M., et
all.2002.p53-Independent Expression of P21
CIPI/WAFIin Plasmacytic Cells During G2 Cells Cycle
Arrest Induced by Actinobacillus actinomycetemcomitans Cyto Lethal Distending
Toxin.Infection and Immunity;70:528-534.
43. Abrhamson J.A.,Lee J.M.,Bernstein A., 1995. Regulation of p53-Mediated Apoptosis
and Cell Cycle Arrest by Steel Factor. Molecular and Celluler Biology;15:6953-6960.
44. Pellegata N.,Antoniono R.J.,Redpath J.L.,Stanbridge E.J.,1996. DNA Damage and
p53-mediated Cellcycle Arrest:A
Reevaluation.Proc.Natl.Acad.Sci.USA;93:15209-15214.
45. Sablino A.A., Ilyinskaya G.V.,Rubtsova S.N.,Aqapova L.S.,Chumakov P.M.,Kopnin
B.P.,1998. Activation of p53-mediated cell cycle checkpoint in Response to
Micronuclei Formation.Journal of Cell Science;111:977-984.
46. Moll.U.,Ostermeyer A.G.,Haladay R.,Winkfield B.,Frazier M.,Zambetti G., 1996.
Cytoplasmic Sequestration of Wild Type p53 Protein Impairs the G1 Checkpoint After
DNA Damage. Molecular and Celluler Biology;16:1126-1137.
47. Pines J. 1997.Tumor Suppressors and Cell Cycle Control.Oncogenes and Tumor
Suppressors.Oxford University Press;p:189-214.
48. Gangopadhyay S.B.,Abraham J., Lin Y.P.,Benchimol S.,1997. The Tumour
Suppressor gene p53. Oncogenes and Tumor Suppressors.Oxford University
Press;p:261-280.
49. Yuwono T., 2005, Biologi Molekular, Penerbit Erlangga, Jakarta
50. Ghobrial I.M.,Witzig T.E.,Adjei A.A.,2005. Targeting Apoptosis Pathways in Cancer
Therapy.CA Cancer J Clin;55:178-194
51. Schuler M.,Green D.R.,2001.Mechanisms of p53-dependent Apoptosis.Biochemical
Society Transactions;29:684-688
52. Murphy M.E., 2000. Ellucidation of the p53- Dependent Apoptosis Pathway.Medical
Science division:p:244-247
53. Allen, J,I,. 1995,. Molecular Biology of Colorectal Cancer : a Clinician’s View,.
Perspect Colon Rectal Surgery., 8: 181 – 202
54. Bruce blumberg,.2000. Oncogenes and Cancer.BioSci 145 A lecture 18.Page 1 – 15
55.Levine A.J., Hu W., Feng Z. 2006. The p53 Pathway: What Questions Remain to be
Explored?.Cell Death and Differentiation.,13:1027-1036
56. Aguda B.D., 2006. Oncogene and Tumor Suppressor gene networks in cell cycle
check points,Apoptosis & cell Survival.
57. Wongpalee S.,2006. RNA interfere (RNAi) Screening of non coding RNAs (ncRNA)
Essential for Cancer Cell Proliferation.
58. Winarto W.P.,2007. Tanaman obat indonesia untuk pengobatan herbal, 1:55-57.
59. Lenny S.,2006. Senyawa Flavonoida, Fenil-propanoida, dan Alkaloida. Departemen
Kimia Fakultas Matematika dan Ilmu Pengetahuan Alam,Universitas Sumatera Utara,
Medan.
Gambar 29.Foto sel karsinoma kolon HT29 tanpa perlakuan (kontrol negatif)
Gambar 30.foto sel karsinoma kolon HT29 dengan perlakuan 5-FU dengan konsentrasi 18,755µl/ml
konsentrasi 37,5µl/ml
Gambar 32.foto sel karsinoma kolon HT29 dengan perlakuan 5-FU dengan konsentrasi 75µl/ml
Gambar 33.foto sel karsinoma kolon HT29 dengan perlakuan 5-FU dengan konsentrasi 150µl/ml
Gambar 34.foto sel karsinoma kolon HT29 dengan perlakuan Bawang Dayak dengan konsentrasi 0,390625µl/ml
konsentrasi 0,78125µl/ml
Gambar 36.foto sel karsinoma kolon HT29 dengan perlakuan bawang dayak dengan konsentrasi 1,51625µl/ml
Bawang dayak
One-Sample Kolmogorov-Smirnov Test
4 13.3350 12.79575 .386 .386 -.270 .772 .591 N Mean Std. Deviation Normal Parametersa,b
Absolute Positive Negative Most Extreme Differences Kolmogorov-Smirnov Z Asymp. Sig. (2-tailed)
PROSEN TASEP53
Test distribution is Normal. a.
Calculated from data. b.
5-fluorouracil
One-Sample Kolmogorov-Smirnov Test
4 2.8825 1.99777 .295 .221 -.295 .591 .876 N Mean Std. Deviation Normal Parametersa,b
Absolute Positive Negative Most Extreme Differences Kolmogorov-Smirnov Z Asymp. Sig. (2-tailed)
PROSEN TASEFU
Test distribution is Normal. a.
Calculated from data. b.
Descriptive Statistics 30.5100 39.97126 5 1.1626 1.23178 5 ekspresip53mutan konsentrasiBD Mean Std. Deviation N Variables Entered/Removedb konsentra siBDa . Enter Model 1 Variables Entered Variables Removed Method
All requested variables entered. a.
Dependent Variable: ekspresip53mutan b. Model Summaryb .663a .440 .254 34.53323 Model 1 R R Square Adjusted R Square Std. Error of the Estimate Predictors: (Constant), konsentrasiBD
a.
Dependent Variable: ekspresip53mutan b. ANOVAb 2813.174 1 2813.174 2.359 .222a 3577.632 3 1192.544 6390.806 4 Regression Residual Total Model 1 Sum of
Squares df Mean Square F Sig.
Predictors: (Constant), konsentrasiBD a.
Dependent Variable: ekspresip53mutan b. Coefficientsa 55.541 22.452 2.474 .090 -15.913 126.994 -21.530 14.018 -.663 -1.536 .222 -66.140 23.081 (Constant) konsentrasiBD Model 1 B Std. Error Unstandardized Coefficients Beta Standardized Coefficients
t Sig. Lower Bound Upper Bound
95% Confidence Interval for B
Dependent Variable: ekspresip53mutan a.
konsentrasiBD 4.00 3.00 2.00 1.00 0.00 100.00 80.00 60.00 40.00 20.00 0.00 Logistic Observed
Descriptive Statistics 22.1480 43.11370 5 56.2500 59.29271 5 ekspresip53mutan konsentasi5FU Mean Std. Deviation N Variables Entered/Removedb konsentasi 5FUa . Enter Model 1 Variables Entered Variables Removed Method
All requested variables entered. a.
Dependent Variable: ekspresip53mutan b. Model Summaryb .560a .314 .085 41.23382 Model 1 R R Square Adjusted R Square Std. Error of the Estimate Predictors: (Constant), konsentasi5FU
a.
Dependent Variable: ekspresip53mutan b. ANOVAb 2334.478 1 2334.478 1.373 .326a 5100.685 3 1700.228 7435.163 4 Regression Residual Total Model 1 Sum of
Squares df Mean Square F Sig.
Predictors: (Constant), konsentasi5FU a.
Dependent Variable: ekspresip53mutan b. Coefficientsa 73.318 29.246 2.507 .087 -19.755 166.390 -.771 .658 -.560 -1.172 .326 -2.864 1.322 (Constant) p53mutan Model 1 B Std. Error Unstandardized Coefficients Beta Standardized Coefficients
t Sig. Lower Bound Upper Bound
95% Confidence Interval for B
Dependent Variable: konsentrasi5FU a.
konsentrasi5FU 5.00 4.00 3.00 2.00 1.00 120.00 100.00 80.00 60.00 40.00 20.00 0.00 Logarithmic Observed
Paired Samples Statistics 30.5100 5 39.97126 17.87569 22.1480 5 43.11370 19.28103 ekspresip53BD ekspresip535FU Pair 1 Mean N Std. Deviation Std. Error Mean
Paired Samples Correlations
5 .966 .007 ekspresip53BD & ekspresip535FU Pair 1 N Correlation Sig.
Paired Samples Test
8.36200 11.22359 5.01934 -5.57393 22.29793 1.666 4 ekspresip53BD -ekspresip535FU Pair 1 Mean Std. Deviation Std. Error
Mean Lower Upper
95% Confidence Interval of the
Difference Paired Differences